Scilex Holding Company has completed the initial tranche of a $150 million Bitcoin investment in Datavault AI, securing significant shares to enhance its portfolio in non-opioid pain management.

Target Information

Scilex Holding Company, based in Palo Alto, California, specializes in acquiring, developing, and commercializing non-opioid pain management products for treating acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases. The company aims to address significant unmet needs within the healthcare sector by focusing on innovative therapies. Their portfolio includes FDA-approved products such as ZTlido®, ELYXYB®, and Gloperba®, which cater to various pain management needs.

As part of its strategic growth initiatives, Scilex has announced the successful closure of the initial tranche of a $150 million Bitcoin investment in Datavault AI Inc. This investment secures Scilex an estimated 278,914,094 shares of Datavault common stock at a nominal price. The initial distribution includes 15,000,000 shares, with further shares to be issued pending stockholder approval.

Industry Overview in the United States

The healthcare industry in the United States is rapidly evolving, particularly with a growing emphasis on non-opioid pain management solutions. With rising opioid addiction rates and regulatory scrutiny surrounding opioid prescriptions, there is a pronou